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A B S T R A C TThe primary outcomes in trials are usually disease-specific measures
(DSMs) designed to be responsive to changes in the condition caused
by treatment. For purposes of cost-effectiveness analysis, treatment
effects on the DSM are often ‘‘mapped’’ into treatment effects on a
generic health-related quality-of-life (QOL) scale, such as EuroQol five-
dimensional questionnaire. Trialists have the option of including
generic QOL measures as trial outcomes. We consider the relative
efficiency (estimate divided by its standard error) of treatment effects
derived from the DSM, the generic QOL, the generic QOL indirectly
estimated from the mapped DSM, and a pooled estimate combining
the direct and indirect information on the generic QOL. By using
a ‘‘common factor’’ theory of the relationship between the DSM and
the generic QOL, we define the circumstances under which indirectly
estimated generic QOL is more efficient than the direct one and when
a pooled QOL estimate is more efficient than the DSM estimate.
As long as the DSM is more responsive, there is always a threshold
sample size above which the indirect estimate has better precisionsee front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2012.09.012
.Lu@bristol.ac.uk.
ondence to: Guobing Lu, School of Social and Comm
S, UK.than the direct estimate. This threshold, however, increases as the
(1) relative responsiveness ratio of the DSM to the generic QOL
increases, (2) precision of the estimated mapping coefficient
increases, and (3) true effect becomes smaller. The pooled estimate
on the generic QOL may be more efficient than the DSM itself unless
the reliability of the DSM is particularly high. Trials powered on DSMs
are likely to have sufficient power to detect treatment effect on the
generic QOL if a pooled estimate is used. We conclude that generic
QOL instruments should be routinely included in randomized con-
trolled trials. Information on mapping coefficients and on relative
responsiveness should be collected more systematically to facilitate
both evidence synthesis and trial design.
Keywords: cost-effectiveness analysis, disease-specific health-related
quality of life, generic health-related quality of life, mapping,
measurement error.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Decisions about which treatments are used are increasingly made
at a national level and based on cost-effectiveness analyses
carried for reimbursement authorities, such as the National
Institute for Health and Clinical Excellence in the United Kingdom.
These decisions rely on demonstrations of cost-effectiveness as
well as clinical efficacy, which is just one component of cost-
effectiveness. Usually, cost-effectiveness analysis requires a mea-
sure of the effect of treatment on patient quality of life (QOL).
Generic measures of health-related QOL such as the EuroQol five-
dimensional (EQ-5D) questionnaire or the Short Form 36 Health
Survey (SF-36) are frequently used for this purpose. Although these
measures may be regarded as essential in an evaluation of the
functional value of new treatments by reimbursement authorities,
regulators and certainly clinicians themselves require demonstra-
tions of efficacy based more closely on measures that are specific
to the clinical area. In many cases, the same disease-specific
measures (DSMs) are used to define eligibility for the trials. Such isthe case in rheumatoid arthritis, for example, where the Health
Assessment Questionnaire (HAQ) [1] is commonly used to assess
both eligibility and outcome. The Psoriasis Area and Severity Index
[2] has the same role in psoriasis and psoriatic arthritis, the Mini-
Mental State Examination in Alzheimer disease [3], and the Beck
Depression Inventory (BDI) [4] and the Hamilton Depression Scale
[5] in depression.
The preference of clinicians for DSMs that directly measure
the pertinent dimensions of patient’s condition is based on the
intuition that these measures are the most ‘‘responsive’’ to
changes in the patient’s condition and thus more suitable for
both monitoring the progress of individual patients and evaluat-
ing the effect of treatment in trials. This intuition is supported
by ample empirical evidence (see Wiebe et al. [6] and citations
therein) and, as we shall see below, by theory. In every field of
medicine, there is a substantial literature on the responsiveness
of DSMs as well as on the relative responsiveness of alternative
DSMs and generic QOL measures. A survey of the sizes and
precision of treatment effects measured on DSM and generic QOLSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
unity Medicine, University of Bristol, Canynge Hall, 39 Whatley
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 1 8 5 – 1 9 4186instruments in a wide range of conditions [6] confirmed that
DSMs are more responsive in the sense that the mean effect size
divided by the SD—the standardized effect size—is higher in
DSMs. It follows from this that for a given trial sample size, the
mean effect divided by its standard error, the t-test statistic, will
also be higher in DSMs. Simply put, a trialist is more likely to be
able to detect a statistically significant treatment effect if a more
responsive measure is used, and this is typically the DSM. Ethical
considerations alone would therefore dictate that the primary
outcome must be the DSM rather than the generic QOL.
The prespecification of one outcome as ‘‘primary’’ is believed to
be a necessary part of trial design [7]. This is a belief that we will
suggest below is unnecessary even in the frequentist framework
that continues to dominate the trial design. Nevertheless, in the
present circumstances, investigators who have in mind that the trial
will be accompanied by an economic analysis can adopt one of two
possible strategies. First, they can choose an accepted DSM as the
primary outcome, and then for the purpose of a cost-effectiveness
analysis the mean treatment effect on the DSM scale is mapped to a
predicted mean treatment effect on some utility scale, such as the
EQ-5D questionnaire. A second strategy would be to measure the
EQ-5D questionnaire directly in the randomized controlled trial. We
call these the ‘‘indirect’’ and ‘‘direct’’ approaches, respectively.
Because the use of DSMs as primary trial outcomes is so
prevalent and because generic measures are often not included
in trials, the indirect strategy, that is, mapping treatment effects
on DSM scales to treatment effects on generic QOL scales [8],
is routinely adopted to facilitate cost-effectiveness analysis.
This article addresses two questions: (1) Which estimate of the
treatment effect on the generic QOL scale is most efficient: an
estimate based on direct measurement of the treatment effect on
the generic scale or an indirect estimate derived by measuring the
treatment effect on the DSM scale and then mapping this to the
generic QOL scale? (2) Which is more efficient: an estimate of
treatment effect based on the DSM or an estimate based on the
direct and indirect information on the generic QOL combined? The
efficiency of an estimate for these purposes can be considered to be
the estimated treatment effect divided by its standard error.
There is a consistent line of thought in the health economics
literature [8,9] that assumes that it must always be preferable to
measure the generic QOL directly. We show below that this is not
necessarily the case. If it is necessary to choose between having
a mapped DSM estimate (indirect) and a generic QOL estimate
(direct) on the basis of efficiency, we will show that there is a
trade-off between the relative responsiveness of the two scales to
treatment effects and the uncertainty in the mapping coefficient.
We then discuss the advantages of a ‘‘pooled’’ estimate of the
treatment effect on the QOL scale on the basis of the information
from both tests. Our approach to both these issues is based on a
structural equation or a common factor model that expresses the
relationship between DSM and QOL scales in terms of common
factors, specific factors, and measurement error [10].
This article is second of a pair of articles based on a particular
model of the relationship between DSMs and generic QOL instru-
ments [10]. The first article sets out a common factor model and
focuses on the properties of mapping coefficients and methods for
estimating them from data. This article begins by setting out a
brief outline of the common factor model, focusing on the
definition of relative responsiveness, on components of total
variance, and on the relationship between mapping coefficients.
We then develop some expressions that allow us to determine the
circumstances in which the direct or indirect estimates, as
described above, will be the most efficient. These mathematical
results are illustrated by using examples from the literature. Next,
we show how the variance of a pooled estimate, combining direct
and indirect estimates, of the treatment effect on the generic QOL
scale can be calculated and compared with the variance of theDSM estimate. This leads us to a definition of the circumstances in
which a combined generic QOL estimate could bemore sensitive to
treatment effects than the DSM estimate. We conclude the article
with a discussion of potential shortcomings in the common factor
model and the need for better information on mapping coeffi-
cients and relative responsiveness.Statistical Methods
Responsiveness in a Factor Loading Model
The factor model and its wider rationale are presented in a
companion article [10]. Here we show the key concepts relevant
to the issue at hand. We imagine that individuals I have been
observed on both DSM Y and a generic QOL Q. We conceptualize
the DSM as consisting of a linear combination of two compo-
nents: y, which is the patient’s true score on a single underlying
attribute that reflects the condition of interest; and e1, which is
the measurement error. The QOL consists of a linear combination
of y, factor x (which is orthogonal to y), and measurement error e2:
Yi¼a1þb1yiþh1e1i
Qi¼a2þb2yiþ fxiþh2e2i
where xi,yi,e1i,e2i ind  N 0,1ð Þ
ð1Þ
The coefficients b1,b2,h1,h2,f are the ‘‘factor loadings.’’ A unit
change in y, for example, caused by a treatment, will generate a
b1 change in Y and a b2 change in Q. This immediately gives us
the mapping coefficient from Y to Q: bY-Q¼b2=b1. Note that the
common factor model (1) leads to a mapping coefficient with
properties that are quite different from the commonly used
ordinary least squares (OLS) regression estimates [8]. In particu-
lar, it takes into account the measurement error in both DSM and
generic QOL and it is symmetrical, that is, bY-Q¼b2=b1 and
bQ-Y¼b1=b2. Note that the factor loadings are study specific,
but indexing for the study has been suppressed for simplicity.
Further details are found in the companion article [10].
The mapping coefficient is, by definition, a ratio of the true
treatment effect on the generic QOL, q, to the treatment effect on
the DSM, dY:
bY-Q¼
q
dY
ð2Þ
The key relationships that allow us to develop implications for
trial size, however, relate to variances and covariances of Y and Q.
Of particular interest here is the partition of the total variance of
scores on each instrument. If we can identify the total variances as
t2Y¼ b21þh21
t2Q¼ b22þ f2þh22
then we can identify the ‘‘reliability’’ of instruments Y and Q in the
sense intended in classical measurement theory as
rY¼
b21
t2Y
rQ¼
b22þ f2
t2Q
ð3Þ
We understand ‘‘measurement error’’ for this purpose to
consist of threats to the reproducibility of test results. This is,
therefore, primarily test-retest reliability, not test consistency as
measured by Cronbach’s a.
For the Q measure, we define another statistic that reflects the
proportion of the total variance that is carried by between-patient
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ryQ¼
b22
t2Q
Note that the ratio of the components of variance represent-
ing between-patient variation in the target attribute y is the
square of the mapping coefficient:
ryQt
2
Q
rYt
2
Y
¼b2Y-Q ð4Þ
The measures rY and r
y
Q can also be regarded as measures of
‘‘responsiveness’’ of each score to causal effects acting on
measure y. If Y was a ‘‘pure’’ measure of y, without any measure-
ment error, then its reliability and responsiveness would be 1.
In the case of Q, responsiveness could be 1 only if there was no
measurement error and if Qwas unaffected by the specific (non-y)
factors, that is, if f was zero. Both kinds of instruments become
less responsive as they become less reliable, that is, as a higher
proportion of variance is taken up by noise. One would expect a
generic QOL instrument to be always less responsive than a DSM
because the former is designed to measure more than just y.
Nevertheless, examples in the literature (discussed below) sug-
gest that this is not always the case. We shall refer the ratio r^Y=r^
y
Q
as the relative responsiveness ratio (RRR) of the DSM to the generic
QOL for attribute y. This is the ratio of the proportions of variance
in each score attributable to between-patient variation in the
attribute of interest, which is the attribute that is causally
changed by the treatment.
In fact, our definitions of responsiveness in terms of para-
meters of the common factor model (1) turn out to be the same as
those commonly used in the clinical epidemiological literature
[6,11]. To see this, we can define the mapping from the standar-
dized treatment effect on DSM Y to the standardized treatment
effect on generic QOL Q and then substitute in Eqs. 2 and 4. Thus,
we obtain
bYðStÞ-QðStÞ ¼
qSt
dYðStÞ
¼ q
tQ
=
dY
tY
¼ tY
tQ
bY-Q¼
tY
tQ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ryQt
2
Q
rYt
2
Y
s
¼
ﬃﬃﬃﬃﬃﬃ
ryQ
rY
s
¼ 1ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
RRR
p
ð5Þ
This reveals that the square root of the RRR gives us the
mapping between the standardized treatment effects; in other
words, it is the ratio of the standardized effect sizes. By the sameTable 1 – Key definitions and relationships based on the comm
Sy
True treatment effects on DSM Y, QOL Q dY ,
Mapping coefficient from Y to Q bY-
Reliability of Y, equivalent to responsiveness of Y rY
Reliability of Q rQ
Responsiveness of Q to changes in attribute y ryQ
Relative responsive ratio Y:Q RR
Variances of Y, Q t2Y ,
Mapping coefficient from Y to Q bY-
Standardized treatment effects on Y, Q dYðS
Mapping between standardized effect sizes bYð
Correlation between DSM Y and QOL Q rYQ
Relationship between RRR and correlation RR
Standard error of the mapping coefficient sb
Precision of estimated mapping coefficient zb¼token, the square root of the RRR is also estimated by the ratio of
the t-test statistics of the null hypothesis of no effect in the
generic QOL and in the DSM. This follows because the t-test
statistics are simply the standardized effects divided by the
square root of the sample sizes. The importance of these
relationships is that they offer a means of obtaining estimates
of responsiveness and relative responsiveness from the statistics
that are commonly reported.
A second set of relationships that can be deduced from the
common factor model (1) relate to the covariance. Under (1) and
using Equation 3, the correlation between Y and Q measures [10]
is given by
r2YQ¼
b21b
2
2
b21þh21
 
b22þ f22þh22
  ¼rYryQ ð6Þ
The correlation is a useful index of the accuracy with which
treatment effects on the DSM can predict treatment effects on
the generic QOL scale. The relationship of the responsiveness of
the measures to changes on the target construct provides a
further means of recovering estimates of the RRR from the
literature. Estimates of the squared correlation, r2YQ , are often
reported as R2, the proportion of total variance accounted for by
regression. Therefore, if an estimate of the test-retest reliability
rY and an estimate of rYQ are available, we can derive a further
estimate of RRR from
RRR¼ rY
ryQ
¼ r
2
Y
r2YQ
ð7Þ
The key relationships and definitions in this section are
summarized in Table 1. Although the rationale for the common
factor model is set out elsewhere [10], readers might note that
these relationships between correlation and relative responsive-
ness could not be deduced from OLS regression. The OLS regres-
sion of a generic QOL against a DSM assumes no measurement
error in the DSM: in other words, rY is implausibly set to 1.
Finally, note that Equation 1 is considered to refer to a specific
study. Many of the variables and coefficients will vary from study to
study. Nevertheless, it is possible to establish that although
reliability and responsiveness are highly study dependent because
they depend on the study-specific patient variance on attribute y,
the mapping coefficient is invariant against changes in this
variance. It can therefore be considered as study invariant, so longon factor model (CFM).
mbols and definitions Source
q Definition
Q¼q=dY Definition, Equation 1
Definition
Definition
Definition
R¼rY=ryQ Definition
t2Q Definition
Q¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ryQt
2
Q=rYt
2
Y
q
CFM, Equation 4
tÞ ¼dY=tY ,dQðStÞ ¼q=tQ Definition
StÞ-QðStÞ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ryQ=rY
q
¼1=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
RRR
p CFM, Equation 5
¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
rYr
y
Q
q
CFM, Equation 6
R¼rY=ryQ¼r2Y=r2YQ CFM, Equation 7
Definition
b=sb Definition
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patients with the target condition [10]. The RRR is not study
invariant, however, as it depends on the ratio of the between-
subject variation in the y attribute of interest to the total variation.
Direct Method: Measurement of Treatment Effect on the QOL
Scale
By considering the relative responsiveness of DSM and generic
measures to mean changes on the target attribute brought about
by treatment, we are now in a position to outline the implications
for trial size. We assume that a proposed trial would generate an
estimate of the mean outcome in each arm on the QOL scale Q.
We would thus have data Qk,t^Qk,nk representing the sample
mean, sample variance, and sample size on arm k, with k ¼ 1
for treatment and k ¼ 0 for control. For simplicity, we will further
assume a pooled variance t^Q and equal sample sizes in each arm
(nk ¼ n). We therefore derive direct estimates of the mean
treatment effect and its variance:
q^dir¼9Q1Q09, Var q^dir
 
¼ 2
n
t2Q ð8Þ
Indirect Method: Mean Treatment Effect from DSM Mapped to
QOL Scale
Here the proposed trial takes DSM Y as its primary outcome. We
would thus have data Yk,Vk,nk representing the sample mean,
sample variance, and sample size on arm k. Assuming again
a pooled sample variance V and equal sample sizes, we have
estimates of the mean treatment effect: d^Y¼9Y1Y09 . This is
mapped to an indirect estimate of the treatment effect on the
QOL scale: q^ind¼ b^d^Y . The variance of the indirectly estimated
measure is a variance of a product of two random variables.
Denoting the expectation of d^Y by dY and the expectation and
variance of b^, respectively, by b and sb
2, we obtain
Var q^ind
 
¼Var b^d^Y
 
¼b2Var d^
 
þd2Ys2bþVar d^Y
 
s2b
¼ 2
n
t2Y b
2þs2b
 
þd2Ys2b ð9Þ
Choice between Directly Measured Generic QOL and Indirect
Mapping from DSM
The investigator should choose the estimate with the minimum
variance. Therefore, the direct method, based on estimating the
treatment effect on the QOL measure in the trial, rather than
mapping it from the disease-specific estimate should be chosen
only if the variance of the mapped estimate is greater than the
variance of the direct estimate, that is, if Var q^dir
 
oVar q^ind
 
.
This condition will be met if
2
n
t2Qo
2
n
t2Y b
2þs2b
 
þd2Ys2b,
or
2
n
t2Qt2Y b2þs2b
 h i
od2Ys2b,
or using 2ð Þ, 2
n
t2Y b
2 rY
ryQ
1
 !
s2b
" #
od2Ys2b
We can gain further insight by transforming from variable Y
to a standardized normal deviate scale by dividing it by the SD tY :
dStðYÞ ¼dY=tY . At the same time, we can divide through by s2b; then
setting zb¼b=sb, we obtain a scale-free measure of the precision of
the estimate of the mapping coefficient. This gives us that the
direct estimate will have a lower variance as long as
d2StðYÞ4
2
n
z2b
rY
ryQ
1
 !
1
" #
ð10ÞBriefly, the threshold increases with both the precision
(squared) of the mapping coefficient zb and the RRR, but it
decreases with the effect size on DSM Y. As this is the threshold
at which the direct estimate is most efficient, we can say that the
indirect estimate becomes more efficient, at any fixed sample size,
if either the precision of the mapping or the RRR increases. Here
we can deduce the following useful results in detail:1. There is a trade-off between the relative responsiveness of the
DSM and QOL measures and the precision zb of the estimated
mapping coefficient.2. If, unusually, the responsiveness of the DSM is less than the
responsiveness of the QOL instruments, that is, rYoryQ , then
the DSM can never be the optimal choice. In fact, the precision
zb of the mapping estimate must exceed
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ryQ=ðrYr
y
Q Þ
q
for
there to be a possibility that the DSM could be optimal.
3. As n-1, the variance of the direct estimate tends to zero.
Thus, there is always some threshold n above which a more
precise estimate can be obtained by measuring the QOL
directly.4. The threshold n becomes higher as the standardized treat-
ment effect becomes smaller.5. As s2b-0, the precision of the mapping coefficient increases
and the indirect estimate will have lower variance as long as
the responsiveness of the DSM is greater than the respon-
siveness of the QOL. Therefore, the threshold n for preferring
the direct measure increases. Similarly, at any value of n there
is always a point at which s2b is so low that the DSM becomes
the optimal measure.6. The lower the RRR (DSM/QOL), the greater the relative preci-
sion of the direct estimate and the lower the n required to
reach the threshold.
Equation 10 would allow trial designers with a particular trial
size and clinically significant effect on the DSM in mind to
determine whether the DSM or the generic QOL was the most
efficient choice.
Another way to express these results is to consider the
criterion value of zb at which the indirect estimate is more
efficient than the direct estimate. Rearranging Equation 10, we
obtain the condition that the indirect estimate is more efficient if
z2b4
d2StðYÞn
2
þ1
 !
rY
ryQ
1
 !,
ð11Þ
As we would expect from the properties that follow from
Equation 10, Equation 11 states that at a fixed precision, the
advantage of the indirect estimate increases as RRR increases but
decreases as the treatment effect on the DSM becomes greater.Direct versus Indirect Estimates: Some Examples
To illustrate how these calculations could play out in practice, we
shall consider some illustrative values of the key parameters
based on the literature and see what kinds of sample sizes are
required before a direct estimate of the QOL gain would be more
efficient than one based on mapping from an estimated effect on
a DSM. First, it is necessary to consider what range of values
should be expected for the RRR. Throughout this discussion, we
treat all health-related QOLs as cardinal measures and when we
refer to the EQ-5D questionnaire this is taken to be the index
value. Furthermore, although preference-based generic QOL
measures are considered preferable in many contexts, we have
treated preference- and non-preference–based measures without
distinction because both have been used in mapping studies and
because both can be represented by the Q measure in the
common factor model (1).
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disease-specific instruments that the mean standardized effect
size in specific instruments was 0.57 compared with that of 0.39
in generic instruments, given a ‘‘typical’’ RRR of (1.46)2 ¼ 2.14.
It was also clear, however, that the ratio depended on the disease
area, being closer to 1 with cardiovascular conditions, around 2
with musculoskeletal conditions, and 7 with pulmonary condi-
tions. Responsiveness of generic QOL measures to neurological
conditions appeared to be exceptionally low. The examples below
were chosen for ‘‘convenience’’: much further research is needed
to determine whether the values are representative. As we are
using them to illustrate the concepts, we will be cautious in
drawing general conclusions that depend on assumptions regard-
ing relative responsiveness.
Mapping from BDI to the EQ-5D Questionnaire
An analysis of the BDI- EQ-5D questionnaire mapping based on
results from a single trial [12] gave estimates of reliability r^Y ¼
0.782, correlation r^YQ ¼ 0.425 [10] (from which we obtain respon-
siveness of Q: r^yQ ¼ 0.231), and RRR ¼ r^Y=r^
y
Q ¼ 3.39 by Equation 7.
The BDI - EQ-5D questionnaire mapping was 0.0134 with a
standard error of 0.0026, giving a mapping precision z^b of 5.15.
Under these conditions, from Equation 7 the sample size per arm
at which it would be more efficient to measure the EQ-5D
questionnaire directly in the trial is 3120 for a ‘‘small’’ standar-
dized effect of 0.2 on the DSM scale, 500 for a ‘‘medium’’ effect of
0.5, and 195 for a ‘‘large’’ effect of 0.8 on the basis of Cohen’s
classification of standardized effect sizes [13].
By using Equation 11, we may conclude that with 500 patients
per arm, for a ‘‘small’’ DSM effect the indirect estimate is more
efficient as long as z^b 4 2, whereas for a ‘‘medium’’ effect, z^b
must exceed 5.2. We suspect that values around 5 for the
precision of the estimated mapping coefficient may be as good
as can be reasonably expected.
Mapping from HAQ to the EQ-5D Questionnaire
An estimate of the HAQ - EQ-5D questionnaire mapping based
on OLS in a large cohort was 0.327, with a standard error of
0.0201 [14]. Although OLS underestimates the true mapping [10],
we will use the estimated mapping precision from this source,
giving z^b ¼ 16.3. The same study reported R2 ¼ r^2YQ between the
HAQ and the EQ-5D questionnaire to be 0.539. If we use an
estimate of the test-retest reliability of the HAQ of 0.91 [15], then
we use relation 7 to obtain an RRR of 0.81  0.81/0.539 ¼ 1.54.
This is somewhat lower than the estimates for musculoskeletal
disorders derived above from Wiebe et al. [6].
There appear to be rather few trials in which both EQ-5D
questionnaire and HAQ scores have been measured. A common
approach to assessing responsiveness is to divide patients into
several groups by using clinical criteria and then examine the
differences between the groups on the DSM and generic QOL
scales. Reconstructing the standardized differences between the
extreme groups in Table 4 of Hurst et al. [16], we estimated the
HAQ/EQ-5D questionnaire RRR to be 1.51. Another method is to
compare changes in patient scores over time, although this is less
reliable than responsiveness based on trials [6]. Marra et al. [17]
reported differences on standardized effect size scales between
patients who were ‘‘worse’’ and patients who were ‘‘better’’ over a
6-month period. There was a 0.31 change on the EQ-5D ques-
tionnaire and 0.46 on the HAQ. This would represent an RRR of
(1.48)2 ¼ 2.2. This gives us a range of estimates between 1.5
and 2.2.
Assuming an RRR of 1.50, a trial in which the true standar-
dized effect sizes were ‘‘small’’ (0.2), ‘‘moderate’’ (0.5), and ‘‘large’’
(0.8), it would require a sample size (per arm) of 6590, 1055, and410 to achieve direct estimates that were more precise than
indirect ones. If RRR is 2.20, then the threshold trial sizes would
be 15,890, 2540, and 990. If such a high level of precision can be
achieved in the mapping coefficient, it appears that the QOL
mapped from the DSM will have a higher precision than the
direct estimate under most imaginable circumstances. With a z^b
of 5 but with the same RRR of 1.5, the superiority of the direct
measure becomes more likely at trial sizes per arm of 575, 92, and
36, respectively.Mappings from HAQ to SF-36, SF-6D, HUI2, and HUI3
The same study [17] also examined change measured on SF-6D,
HUI2 and HUI3 (Health Utilities Index Mark 2 and Mark 3)
measures. The RRR of the HAQ relative to each of these measures
was 1.39, 1.09, and 1.94, respectively, suggesting that some of
these generic measures are relatively responsive to changes in
rheumatoid arthritis.
Although this study did not report SF-36, this generic QOL is of
interest because it is relatively unabbreviated and may have the
potential to be a relatively reliable and responsive measure.
Although it is not a preference-based measure, mapping to and
from SF-36 is often undertaken for similar purposes and its
responsiveness to change in many clinical conditions has been
widely discussed. We identified six trials of biologic therapies for
psoriatic and rheumatoid arthritis that ran between 1994 and
2011, which reported treatment effects on the HAQ and SF-36
Physical Components Summary (PCS) that have been used in
National Institute for Health and Clinical Excellence technology
appraisals [18,19]. Five trials reported results from which a total
of 10 t tests could be constructed on both outcomes. In 7 of these
cases, the t-test statistic for the SF-36 PCS was greater than that
for the HAQ. This is the situation in which it can never be optimal
to map from the DSM as the indirect measure suffers from both a
lower inherent responsiveness and the error in the mapping
coefficient. In the remaining 3 cases, where the HAQ was more
responsive, the RRR was 1.25 or less.
The relationships between relative responsiveness, z^b, sample
size, and treatment effect are shown in Figure 1. These graphs
show, for ‘‘small,’’ ‘‘medium,’’ and ‘‘large’’ effect sizes on the DSM,
the threshold zb above which the indirect estimate is more
efficient. By the same token, the graph can be seen as showing
the threshold sample sizes (to the right of the lines) above which
the direct measure is more efficient.Advantages of Pooling QOL and DSM Treatment
Effects
We have answered the question ‘‘Which outcome should be
measured in trials: DSM or QOL?’’ by showing that there is a
trade-off between the relative responsiveness of the two mea-
sures to causal changes in their target attribute and the precision
with which the mapping is known. In this final section, however,
we argue that the answer should in fact be ‘‘Measure both!’’
Although trials are powered to detect differences on the DSM and
the DSM is thus regarded as the ‘‘primary’’ end point, there is no
general objection to measuring more than one outcome, and it
is therefore reasonable to demonstrate the beneficial effect of
pooling the direct estimate from the QOL instrument and the
indirect estimate based on the ‘‘mapped’’ treatment effect on the
DSM to find a single combined within-trial pooled estimate.
In carrying out this calculation, we need to only take into account
the correlation between the QOL and the DSM, which, under the
common factor model (1), arises from both scores sharing the
common factor y.
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Fig. 1 – Threshold value of zb, the precision of the mapping coefficient, above which the indirect estimate of the treatment
effect on the generic QOL scale is more efficient than the direct estimate, as a function of trial size and relative
responsiveness ratio. Treatment effect on the DSM is (A) ‘‘small’’ (d ¼ 0.2), (B) ‘‘medium’’ (d ¼ 0.5), and (C) ‘‘large’’ (d ¼ 0.8).
DSM, disease-specific measure; RR, relative responsiveness; QOL, quality of life.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 1 8 5 – 1 9 4190There are, in all, four treatment effect estimates to consider:
(1) the generic QOL measured directly, (2) the DSM measured
directly, (3) the DSM measure mapped to the QOL scale, and
(4) the combined estimate obtained by pooling the information in
the QOL measured directly and indirectly through the mapped
DSM. To facilitate the comparison, we will place all effects on a
standardized scale—whether DSM or generic QOL—to remove
dependencies on the original scales of measurement. The divi-
sion of effect sizes by SDs is no more than rescaling and has no
effect on the relative efficiency of the estimates of effect.
We begin by developing expressions for the variances of each of
the four treatment effect estimates based on a trial with a sample
size n in each arm.
Treatment Effect Based on Generic QOL Measured Directly
By starting from our estimate of the variance of the mean
treatment effect q^dir (8), we obtainVar q^dir
 
¼ 2
n
t2Q , Var q^
dir
St
 
¼ 2
n
ð12ÞTreatment Effect Based on DSM
The square root of the relative responsiveness is the ratio of the
standardized effects. Thus, if the variance of a standardized QOL
score is 2/n, then the variance of the standardized DSM score is
given by
Var d^YðStÞ
 
¼ 2
n
 
rYQ
rY
ð13Þ
This can be readily confirmed by considering the variance that
would be induced in Y and in Q if there was a unit variance in the
common factor y.
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The variance of q^ind¼ b^d^Y was given by Equation 9. By making
a series of substitutions on the basis of the relations
ryQt
2
Q=rYt
2
Y¼b2Y-Qand d2Y¼d2Q=b2 and by further dividing through
by t2Q, we obtain an expression in the standardized generic QOL
scale:
Var q^indSt
 
¼ 2
n
ryQ
rY
1þ 1
z2b
 !
þ q
2
St
z2b
ð14Þ
Variance of the Pooled Generic QOL Treatment Effect by
Combining Direct and Indirect Estimators
To combine the two estimators q^dirSt and q^
ind
St , we need to take into
account their correlation, which arises from the common factor y
in both the DSM and generic QOL scores. From (1), the covariance
of the two estimates is
Cov q^dir,q^ind
 
¼Cov Q1Q0,b^ Y1Y0
  
¼b Cov Q1,Y1
 þCov Q0,Y0 	 
¼ 2n b
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
rYr
y
Q
q
tYtQ
Thus, the two estimates have the following bivariate distribu-
tion:
q^dir
q^ind
0
@
1
AN dQ
dQ
 !
,
2
n
t2Q b
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
rYr
y
Q
q
tQtY
b
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
rYr
y
Q
q
tQtY t2Y b
2þs2b
 
þn2d
2
Ys
2
b
0
B@
1
CA
0
B@
1
CA
Once again, we can divide the estimates by tQ and the
variances and covariances by t2Q to obtain results for standar-
dized generic QOL scores and then use Equation 3, eventually
giving
q^dirSt
q^indSt
0
@
1
AN qSt
qSt
 !
,
2
n
1 ryQ
ryQ
ryQ
rY
1þ 1
z2b
 
þq2St
z2b
0
BB@
1
CCA
0
BB@
1
CCA ð15Þ
When two correlated estimates of the same quantity are
pooled, the variance of the pooled estimate depends on the
correlation (see section on ‘‘Variance of the Pooled Estimate of
the Common Mean from Two Measurements’’). Applying this to
Equation 15, we obtain the variance of the pooled estimate:
Var q^pooledSt
 
¼
2
n
ryQ
rY
1þ 1
z2b
 
þq
2
St
z2b
 ryQ
 2 
1þr
y
Q
rY
1þ 1
z2b
 
þq
2
St
z2b
2ryQ
ð16Þ
We can now say that the pooled estimate will be more
efficient than an estimate based on the DSM itself if
Var q^pooledSt
 
oVar d^YðStÞ
 
. This condition is met if (see section
on ‘‘Derivation of Equation 17’’ for the derivation)
z2b4
1þd2YðStÞ
  rY
ryQ
1
 !
1rY
 2 ð17Þ
Note that the condition for the pooled estimate to be better
than the mapped one depends on the size of the treatment effect,
but not on the sample size. Two further conclusions can be drawn
immediately: First, the pooled estimate becomes more attractive
as the precision of the mapping coefficient zb increases and also
as the relative responsiveness decreases. Second, and perhaps
more importantly, the possibility that the pooled estimate is
more efficient becomes increasingly remote as the reliability of
the DSM becomes greater. This reminds us that it is only the
measurement error in the DSM that causes there to be anadvantage in pooling the information that it contains changes
in y with information on other tests that are also sensitive to y.
If there was no measurement error in the DSM, then nothing
further can be learned about the treatment effect on the common
factor y by also measuring the QOL. The generic QOL might, of
course, carry information about the treatment effect on other
dimensions that are orthogonal to y, but a treatment effect on
these dimensions could not be pooled with the DSM.
Equation 17 can be recast in a form analogous to Equation 10:
d2YðStÞo
z2b 1rY
 2
rY
ryQ
1
 ! 1 ð18Þ
If this condition is true, then the trial designer should prefer
the pooled response; if not, then the DSM.
With the values for relative responsiveness of 3.29 and
reliability of 0.782 obtained in the previous BDI - EQ-5D ques-
tionnaire illustration, we would require zb 4 7.2 in a trial aiming
to find a ‘‘small’’ dY(St) ¼ 0.2 on the standardized DSM scale and
zb 4 7.9 for a ‘‘medium’’ effect. These values appear to be
moderately demanding. The calculation is very sensitive to
reliability. If we take the 0.91 estimate of the reliability of the
HAQ and we use a typical relative responsiveness of 1.5, then we
obtain zb 4 8.0 for a small effect and zb 4 8.8 for a medium
effect. With relative responsiveness at 2, these thresholds are
11.3 and 12.4. Having mapping coefficients estimated with this
level of precision appears to be demanding, and the prospect that
a pooled QOL estimate would be more efficient than a DSM
estimate seems remote in this case. On the other hand, 0.91 is at
the upper end of reliability estimates, and values between 0.7 and
0.8 would be more usual.
At these lower levels, as long as relative responsiveness is less
than 2 the conditions under which the pooled QOL estimate is
more efficient than the DSM estimate become relatively easy to
meet. Figure 2 shows the value of zb above which the pooled
estimate on the QOL scale is more efficient than the directly
measured DSM as a function of effect size, relative responsive-
ness, and DSM reliability. These results suggest that a pooled
estimate of the QOL effect competes with the DSM itself in
efficiency. This means that trials powered on DSM will in
many—perhaps most—cases have adequate power to detect
QOL differences as well. More broadly, the common factor
approach makes efficient use of data if results are reported for
both QOL and DSM.Discussion
Although trial designers tend to consider DSMs as the ‘‘primary’’
outcome in trials, the health economist wishes to know what the
effect of treatment has been on patient’s QOL. For this purpose
the treatment effects on the DSM scale are mapped to treatment
effects on a generic QOL scale, such as the EQ-5D questionnaire,
which is typically not measured in trials. The mapping coefficient
is therefore derived from external data. This situation arises
quite commonly, because the DSM is more sensitive to treatment
effects than generic QOL measures, and is thus preferred by
trialists who wish to maximize the chance of demonstrating an
effect and minimize the trial size required by choosing the most
responsive outcome measure.
It is often assumed that a direct estimate of the treatment
different on the generic QOL scale would be more efficient, that
is, have lower variance, than the mapped measure [8]. On the
basis of a common factor model of the relationship between the
DSM and the generic QOL [10], we have demonstrated that this
is not necessarily the case. Instead, there is a trade-off between
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Fig. 2 – Threshold value of zb , the precision of the mapping coefficient, above which a pooled estimate of the generic QOL
treatment effect is more efficient than an estimate of the DSM treatment effect, as a function of the reliability of the DSM and
the relative responsiveness ratio. Treatment effect on the DSM is (A) ‘‘small’’ (d ¼ 0.2), (B) ‘‘medium’’ (d ¼ 0.5), and (C) ‘‘large’’
(d ¼ 0.8). DSM, disease-specific measure; RR, relative responsiveness; QOL, quality of life.
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responsiveness of the DSM and the generic QOL measures. If
the mapping were known perfectly, the mapped measure
would always have lower variance (as long as the DSM
was more responsive than the generic QOL). Nevertheless,
because there is a degree of error in the mapping coefficient,
there will always be a trial size at which the direct estimate is
superior.
Of course, a discussion on the relative merits of the directly
measured generic QOL and the mapped estimate derived from
the DSM starts from a premise that the trial has been powered to
detect a specified difference in the DSM. This is not unreason-
able, because, based on the superior responsiveness of the DSM,
the less responsive measure would demand more patients and
would therefore be considered unethical in the classicalframeworks for trials. The result is, however, that trials that are
powered to detect DSM effects are almost inevitably underpow-
ered to detect effects on the generic QOL scale.
It is therefore of interest to consider the advantages of a
pooled estimate of the treatment effect on the generic QOL scale,
combining the directly observed QOL with a mapped estimate.
In the present context, it is clear that the pooled estimate must be
more efficient than either the direct QOL or the indirect QOL
mapped from the DSM. We have shown, however, that the pooled
estimate can sometimes be more efficient than the direct DSM,
particularly when its reliability is only moderate or low or when the
mapping is quite precisely known. This means that a study powered
to detect a given difference on the DSM may well be able to detect
an equivalent difference on a generic QOL measure if direct and
indirect information is pooled. This is significant because it indicates
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 1 8 5 – 1 9 4 193that trials can be powered for ‘‘economic,’’ that is, QOL, outcomes
without necessarily requiring higher sample sizes.
The study addresses choices open to trialists. In practice,
trialists tend to start with an idea of the likely trial size and
a clinically meaningful effect size on the DSM scale. If a choice
must be made between the two instruments, provided that the
precision of the mapping coefficient and the responsiveness of
both the DSM and the generic QOL instruments are known,
Equation 10 can be used to determine the most efficient way
to obtain an estimated treatment effect on the generic scale.
A further question that arises is whether to power a trial on the
basis of the clinical (DSM) or ‘‘economic’’ (generic QOL) outcome.
If it is possible to include both measures, we may summarize the
choices available to the trial designer as follows: In powering
a study, the mapped DSM will always be inferior to the DSM itself
because the former includes the error in the mapping. The
generic QOL is usually inferior to the DSM unless it is more
responsive. This is unusual, but the comparison between the
SF-36 PCS and the HAQ in rheumatoid arthritis suggests that it is
not impossible. Finally, if there is an option to include both
measures, then Equation 17 can be used to decide whether it is
more efficient to power on the basis of the DSM alone or on the
pooled effect combining the direct QOL effect with the indirect
effect mapped from the DSM.
The usefulness of our approach depends on the validity of the
factor model and the extent to which there is information on the
relative responsiveness of the test instruments and the mapping
coefficient and its precision. We examine these issues in turn.
The common factor model (1) is probably the simplest possible
account of the relationship between a DSM and a generic QOL, and
conclusions drawn from it depend, to some extent, on the
assumptions it makes. The underlying rationale for the common
factor model is set out in detail in a companion article [10]. Among
the key assumptions that bear on the present article are the
independence of the measurement error in the two tests, which
would affect estimates of the RRR based on correlation and
especially the characterization of the DSM as reflecting a unidi-
mensional attribute plus measurement error. In some areas, such
as depression, factor analysis has tended to show that the under-
lying measures are largely unidimensional [20]. For, say, rheuma-
toid arthritis, this is less likely to be true, and for multisystem
diseases such as ankylosing spondylitis or Alzheimer disease, this
is still less plausible. The common factor model could, of course, be
elaborated in many ways to encompass multidimensionality, but in
defense of the simple form in which we have presented it, it needs
to be emphasized that its focus is on mapping between mean
treatment effects rather than between individual scale responses.
The assumption of unidimensionality at this level may be less
demanding as it only requires that the treatment be approximately
equally effective on all the ‘‘dimensions’’ to which the DSM is
sensitive. This would probably be the case if the response to
treatment occurred in several domains but through a single
common pathway. For example, an anti-inflammatory drug in
rheumatoid arthritis may relieve functional impairment, pain,
and depression through a single mechanism. Although one might
not think of this as a unidimensional effect, the common factor
model as presented would still apply. An example of where the
model would break down would be if treatment produced adverse
side effects that were reflected in the generic QOL measure, but not
the DSM measure.
The adequacy of such assumptions is an empirical issue, and
the model’s sensitivity to them can also be studied further
through simulation. Nevertheless, the common factor is elabo-
rated and the essential conclusions from this article are unlikely
to be altered. First, the treatment effect on the generic QOL scale
indirectly estimated from mapping the DSM may, in some
circumstances, have less error than the QOL measured directly,and this will depend on the relative responsiveness of the two
measures to changes in the condition resulting from treatment
and on the precision in the estimate of the mapping coefficient.
Second, unless the DSM is a highly reliable measure, specifically
with high test-retest reliability, a trial powered on a DSM may
have adequate power to detect a difference on the QOL scale if an
estimate of the QOL effect is based on a pooling of the direct and
indirect estimates. For these reasons, we would urge trial
designers to include generic QOL instruments among the trial
outcomes.
The responsiveness of tests to change in the underlying
condition, measured clinically, is widely studied, and there is
also a substantial psychometric literature for both specific and
generic health-related QOLs focusing on various measures of
reliability. There has been much less work, however, on the
quantitative estimates of relative responsiveness of the various
DSMs and generic QOL instruments available in different sets
of patients. The values used in this article have been ‘‘gleaned’’
from the literature in a variety of ways, and there can be little
doubt that systematic exploration of the literature would be
highly informative. It would not only tell us about relative
responsiveness but also provide opportunities to further develop
the common factor theory. Our apparent finding that the respon-
siveness of SF-36 PCS most likely exceeds that of the HAQ in
rheumatoid and psoriatic arthritis is, perhaps, an indication of
the value of a more quantitative approach.
Similarly, although mapping of treatment effects has become an
almost routine practice in health technology assessment, the map-
ping coefficients that are used in practice appear in many cases to
be plucked from single studies in a rather arbitrary way. In a
companion article, we argue that the use of OLS regression routinely
underestimates mapping coefficients [10], but even if this is set aside,
it is clear that careful quantitative work to evaluate the constancy of
the mapping coefficient across studies—a fundamental assumption
however they are estimated—is lacking, and insufficient attention
has been given to either the statistical precision of estimates or
uncertainty in the models on which they are based. The ideas
presented here make it clear that more research is required to
obtain robust and reliable estimates of mapping coefficients, as
these have an essential role in both evidence synthesis and trial
design.
Variance of the Pooled Estimate of the Common Mean from
Two Measurements
If two scores Y1 and Y2 have a bivariate normal distribution with
common mean m and known variances s1
2, s2
2 and correlation
coefficient r, then the maximum likelihood estimate of m is given
by
m^pooled¼ 1
w1þw2
w1Y1þw2Y2ð Þ where w1¼s22rs1s2, w2¼s21rs1s2
with variance
Var m^pooled
 
¼ 1r
2
 
s21s
2
2
s212rs1s2þs22
This can be deduced straightforwardly from a standard result
in multivariate statistics on the estimate of normal mean when
covariance matrix is known [21]. Note that when r ¼ 0, that is,
Y1 and Y2 are independent, the above result is just the inverse-
variance-weighted estimate in meta-analysis.
Derivation of Equation 17
Equation 16 gives the conditions under which a pooled estimate
of the standardized treatment effect on the generic QOL scale has
lower variance than the standardized treatment effect on the
DSM, that is, Var q^pooledSt
 
oVar d^YðStÞ
 
. Based on (13) and (15),
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2
n
ryQ
rY
1þ 1
z2b
 
þq
2
St
z2b
 ryQ
 2 
1þr
y
Q
rY
1þ 1
z2b
 
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2
St
z2b
2ryQ
o 2
n
ryQ
rY
Setting R¼rY=ryQ , we obtain
1þ 1
z2b
þ Rq
2
St
z2b
R ryQ
 2
o1þ 1R þ 1Rz2b þ
q2St
z2b
2ryQ
1þRq2StRz2b ryQ
 2
o
z2b
R
þ 1
R
þq2St2z2bryQ
z2b4
1þRq2St 1=R
 q2St
1=R
 2ryQþR ryQ 2
z2b4
1þRq2St
 
R1ð Þ
1RryQ
 2
Finally, noting that Rq2St¼d2YðStÞ from Equation 5 and recalling
that RryQ¼rY , which is the reliability of the DSM, we obtain
z2b4
1þd2YðStÞ
 
R1ð Þ
1rY
 2
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